Nanoparticles for drug delivery have been designed with all sorts of practical shapes in mind, many of them offering a unique way to hold or release drugs, or to accurately target certain diseases. But researchers at Georgia Tech and other U.S. universities have found that nanoparticles shaped like discs are optimal for gaining entry into human cells.
Alnylam is pushing its latest RNAi drug through early clinical trials, highlighting the company's delivery platform that enables an effective gene-silencing treatment. This time, the RNA specialist published results from a successful Phase I study of its cholesterol drug ALN-PCS.
Researchers at Massachusetts General Hospital have shown that a proven hypertension drug can help chemotherapy infiltrate solid tumors by opening up collapsed blood vessels in the cancerous mass.
New Jersey's John Theurer Cancer Center published two studies recently demonstrating the success of two oral formulations to treat refractory mantle-cell lymphoma, a particularly challenging form of non-Hodgkin's lymphoma that leads to chemoresistance over time.
Small New Jersey delivery specialist Enteris BioPharma, which only just opened its doors in April of this year, entered a licensing agreement for an undisclosed amount with Dutch Nordic Bioscience for Enteris's oral-delivery tech for peptides and small molecules.
The ring, which delivers a powdered version of the antiretroviral drug tenofovir for up to 30 days at a time, showed a 100% success rate in animal models and will enter a clinical trial in November.
Getting vaccines to stay in mucosal membranes long enough to trigger an immune response can be tricky. Engineers have now developed nanoparticles to carry vaccines to the mucosal surface in the lungs, protecting them long enough to provoke an immune response.
Medtronic took a giant leap forward Friday as the FDA approved one of those versions, its MiniMed 530G device with Threshold Suspend technology. While the auto-shutoff feature doesn't quite make this MiniMed design the fully automated, closed-loop artificial pancreas the industry has been chasing for years, its approval does represent the beginning of next-generation insulin delivery, as well as a major success in the field for Medtronic.
BioTime, the Alameda, CA-based maker of a hydrogel technology for drug delivery, signed an exclusive sublicense agreement with Jade Therapeutics to allow the Utah company to use the hydrogel in its own sustained-release treatments for the eye.
To improve the delivery of intravenous drugs, researchers have developed a computerized system that not only determines the exact dosage but also identifies the contents of a fluid in the IV line in real time.
In another step forward for the artificial pancreas, researchers in the U.S. have performed the first successful clinical trial using the device along with fast-acting inhaled insulin to enhance insulin intake during mealtimes for patients with Type 1 diabetes.
The 4-year-old startup develops cancer-drug delivering catheters, which are designed to administer treatment directly to tumors through a process called chemoembolization.
Alnylam, a specialist in RNAi drug delivery, welcomed positive results in an early-stage trial of its treatment designed to silence the gene that causes a rare, deadly form of the disease amyloidosis. The data establish human translation for Alnylam's conjugate delivery platform, the company says.
Bind Therapeutics, currently developing a nanotech delivery platform for cancer, raised $70.5 million in a public offering of 4,700,00 shares at $15 each. The company began trading Friday under the ticker symbol "BIND."
Delivery specialist Mystic Pharmaceuticals snagged U.S. patents for two of its platforms, VersiDoser for liquid ophthalmic and intranasal drugs and VRx2 for intranasal powders--the devices are used to treat ocular, CNS, neurodegenerative and infectious diseases.
Have you ever watched a beetle walk across the ceiling, appearing to defy the laws of gravity? What you're seeing is "wet adhesion," widely used in nature by insects and the like, and researchers in Taiwan are employing their crafted version of the technique to make patches that release drugs into the skin.
The drug delivery device--combining an insulin pump with a glucose monitor for complete, automated control over insulin dosage--has occupied the sights of several big names in the diabetes arena, giving rise to several iterations currently moving forward in clinical trials. But who is ready to land the coveted approval first? And is the technology effective enough to facilitate an immediate payoff?
Profectus BioSciences, a vaccine developer with a focus on DNA-based applications, began a Phase I clinical trial of its HIV vaccine, which makes use of the TriGrid electroporation delivery system the company licensed from Ichor Medical Systems.
Researchers from the U.S. and South Korea have developed an intelligent delivery system using a structure much like a corked bottle that releases a drug payload when triggered by a rise in temperature.
Florida-based Veritas Bio won approval from the European Patent Application for its delivery technique for RNA-based drugs. The technology enables small pieces of RNA, which can be used to "silence" genetic traits, to reach the liver and treat diseases affecting the organ.